Ascentage Pharma reported a 90% year-over-year increase in product sales for 2025, reaching $82.1 million, fueled by an 81% rise in Olverembatinib sales to $62.2 million and $10.1 million from Lisaftoclax since its mid-2025 launch. The company is advancing multiple Phase III clinical trials globally, including FDA and EMA-cleared studies, supporting its pipeline growth. Despite a net loss of $177.7 million due to increased R&D and commercialization costs, Ascentage Pharma strengthened its cash position with proceeds from public offerings. The company plans to continue expanding clinical trials and pursue inclusion of Lisaftoclax in China's National Reimbursement Drug List in 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
